enVVeno announces 97% clinical improvement in 6-month VenoValve Pivotal Trial; aims for Q4 2024 FDA approval.
enVVeno Medical Corporation announced positive topline efficacy data from its VenoValve Pivotal Trial, showing significant clinical improvement in 97% of patients at six months, as measured by the Revised Venous Clinical Severity Score (rVCSS). 74% of patients showed a meaningful benefit with a 3-point or more improvement in rVCSS. The company aims to file for VenoValve FDA approval in Q4 2024.
March 06, 2024
4 Articles